Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LPL | P06858 | 9/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2489484 | 0.88 | ALDH1A1 (0.56) | ATMTDP1LPLLIPGALDH1A1 | |
| SCHEMBL28452550 | 0.85 | CA1 (0.40) | LPLLIPGALDH1A1HIF1ACA1 | |
| SCHEMBL3678053 | 0.83 | MAPT (0.45) | LPLLIPGALDH1A1CA1CA2 | |
| SCHEMBL29398685 | 0.83 | MAPT (0.45) | LPLLIPGALDH1A1CA1CA2 | |
| SCHEMBL23830122 | 0.82 | ALDH1A1 (0.40) | ATMTDP1LPLLIPGALDH1A1 | |
| SCHEMBL1065935 | 0.82 | TDP1 (0.49) | TDP1LPLLIPGALDH1A1CA1 | |
| SCHEMBL28453522 | 0.82 | TSHR (0.49) | TDP1LPLLIPGALDH1A1CA1 | |
| SCHEMBL28452806 | 0.82 | LPL (0.39) | TDP1LPLLIPGCA1CA2 | |
| SCHEMBL1284877 | 0.82 | GPR35 (0.51) | TDP1LPLLIPGALDH1A1HIF1A | |
| SCHEMBL20136292 | 0.81 | CA1 (0.40) | LPLLIPGALDH1A1HIF1ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111574426-A | Diamine monomer containing isoindigo structure and black polyimide synthesized from diamine monomer | 湘潭大学 | 2020-08-25 | — | — | CN | claimed |
| WO-2026107424-A1 | N-(4-(IMIDAZO[4,5-B]PYRIDIN-5-YL)-2-PYRIDYL)BENZAMIDE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026107418-A1 | N-(4-(1H-BENZO[D[IMIDAZOL-6-YL)-PYRIDIN-2-YL)BENZAMIDE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026107420-A1 | N-(4-(1H-BENZO[D[IMIDAZOL-6-YL)-PYRIDIN-2-YL)BENZAMIDE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026107425-A1 | 5-(PYRIDIN-4-YL)-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| EP-3508204-B1 | QUINAZOLIN-8-YL DERIVATIVES FOR USE IN METHODS OF TREATING MELANOMA, NON-SMALL CELL LUNG CANCER, THYROID CANCER, OVARIAN CANCER, OR COLON CANCER | NEUPHARMA INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | disclosed |
| CN-116444499-B | Phenylalanine derivative containing 4-quinazolinone and preparation method and application thereof | 山东大学 | 2024-09-06 | — | — | CN | disclosed |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
| EP-2068869-A2 | NOVEL IMIDAZOTHIAZOLES AND IMIDAZOXAZOLES | Abbott Laboratories (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080161341-A1 | Novel imidazothiazoles and imidazoxazoles | ABBVIE INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161341-A1 | Novel imidazothiazoles and imidazoxazoles | ABBVIE INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161341-A1 | Novel imidazothiazoles and imidazoxazoles | ABBVIE INC. | 2008-07-03 | — | — | US | disclosed |
| WO-2008063287-A2 | NOVEL IMIDAZOTHIAZOLES AND IMIDAZOXAZOLES | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063287-A2 | NOVEL IMIDAZOTHIAZOLES AND IMIDAZOXAZOLES | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | ATM 362/4885TDP1 1037/4885LPL 3730/4885 |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | CDK4, CDKL4, MKI67 | ATM 2164/4885TDP1 493/4885LPL 3508/4885 |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | CDK4, CDKL4, MKI67 | ATM 2213/4885TDP1 446/4885LPL 3425/4885 |
| US-20080161341-A1 | Novel imidazothiazoles and imidazoxazoles | MAP3K1, MAP3K19, MAP3K5 | ATM 814/4885TDP1 2329/4885LPL 4598/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | ATM 3283/4885TDP1 2058/4885LPL 4355/4885 |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | BRAF, TTK, MAP4K2 | ATM 102/4885TDP1 1468/4885LPL 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.